Hot flushes: Are there effective alternatives to estrogen?

Menopause International

Volumn 16, Issue 2, 2010, Pages 81-88

  Sassarini, Jenifer ^a   Lumsden, Mary Ann ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

alternatives; hormonal; Hot flushes; non hormonal

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA TOCOPHEROL; BAZEDOXIFENE; CIMICIFUGA RACEMOSA EXTRACT; CLONIDINE; CONJUGATED ESTROGEN; DESVENLAFAXINE; ESTRADIOL; ESTRADIOL VALERATE; ESTRIOL; ESTROGEN; ETHINYLESTRADIOL; FLUOXETINE; GABAPENTIN; MEDROXYPROGESTERONE ACETATE; NORADRENALIN; NORETHISTERONE; PAROXETINE; PHYTOESTROGEN; PIPERAZINE ESTRONE SULFATE; PRIMROSE OIL; PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TIBOLONE; UNINDEXED DRUG; VENLAFAXINE;

ACUPUNCTURE; BREAST CANCER; CANCER RISK; CIMICIFUGA RACEMOSA; CLIMACTERIUM; CLINICAL PRACTICE; DEPRESSION; DIETARY INTAKE; DISEASE SEVERITY; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ESTROGEN ACTIVITY; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; EXERCISE; FEMALE; GANGLION BLOCK; HERBAL MEDICINE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYSTERECTOMY; LIVER TOXICITY; MAMMOGRAPHY; MENOPAUSAL SYNDROME; MENOPAUSE; NEW ZEALAND; NIGHT SWEAT; NONHUMAN; OVARIECTOMY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; RECURRENT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; SKIN TEMPERATURE; STELLATE GANGLION; SYMPTOM; THERMOREGULATION; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES; UNSPECIFIED SIDE EFFECT; VAGINA ATROPHY; VENOUS THROMBOEMBOLISM; VITAMIN INTAKE; WOMEN'S HEALTH;

ACUPUNCTURE THERAPY; AMINES; CIMICIFUGA; CLONIDINE; CYCLOHEXANECARBOXYLIC ACIDS; ESTROGEN REPLACEMENT THERAPY; EXERCISE; FEMALE; GAMMA-AMINOBUTYRIC ACID; GREAT BRITAIN; HOT FLASHES; HUMANS; MENOPAUSE; NEW ZEALAND; NORPREGNENES; PHYTOESTROGENS; PROGESTERONE; SEROTONIN UPTAKE INHIBITORS; SKIN; UNITED STATES; VITAMIN E;

EID: 77955875684     PISSN: 17540453     EISSN: 17540461     Source Type: Journal    
DOI: 10.1258/mi.2010.010007     Document Type: Review

References (81)

1. Molnar GW. Body temperatures during menopausal hot flashes. J Appl Physiol 1975; 38: 499–503
2. Sturdee DW, Reece BL. Thermography of menopausal hot flushes. Maturitas 1979; 1: 201–205
3. Freedman RR. Laboratory and ambulatory monitoring of menopausal hot flashes. Psychophysiology 2007; 26: 573–579
4. Kronenberg F, Cote LJ, Linkie DM, Dyrenfurth I, Downey JA. Menopausal hot flashes: thermoregulatory, cardiovascular, and circulating catecholamine and LH changes. Maturitas 1984; 6: 31–43
5. Casper RF, Yen SSC. Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin Endocrinol 1985; 22: 293–312
6. Stearns V, Ullmer L, Lopez J, Smith Y, Isaacs C, Hayes DF. Hot flushes. Lancet 2002; 360: 1851–61
7. Shanafelt TD, Barton DL, Adjei AA, Loprinzi C. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002; 77: 1207–18
8. Freedman RR, Norton D, Woodward S, Cornelissen G. Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab 1995; 80: 2354–8
9. Freedman RR. Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Fertil Steril 1998; 70: 332–337
10. Freedman RR. Core body temperature during menopausal hot flushes. Fertil Steril 1996; 65: 1141–4
11. Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am J Obstet Gynecol 1999; 181: 66–70
12. Freedman RR, Blacker CM. Estrogen raises the sweating threshold in postmenopausal women with hot flashes. Fertil Steril 2002; 77: 487–90
13. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral estrogen and combined estrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; (4): CD002978
14. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004; 291: 1610–20
15. Loprinzi CL, Michalak JC, Quella SK,, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331: 347–52
16. Schiff I, Tulchinsky D, Cramer D, Ryan KJ. Oral medroxyprogesterone in the treatment of postmenopausal symptoms. J Am Med Assoc 1980; 244: 1443–5
17. Nordin BEC, Jones MM, Crilly RG, Marshail DH, Brooke R. A placebo-controlled trial of ethinyl oestradiol and norethisterone in climacteric women. Maturitas 1980; 2: 247–51
18. Prior JC, Nielson JD, Hitchcock CL, Williams LA, Vigna YM, Dean CB. Medroxyprogesterone and conjugated estrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy. Clin Sci 2007; 112: 517–25
19. Loprinzi CL, Levitt R, Barton DL,, et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: north central cancer treatment group trial N99C7. J Clin Oncol 2006; 24: 1409–14
20. Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999; 94: 225–228
21. Wren BG, Champion SM, Willetts K, Manga RZ, Eden JA. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause 2003; 10: 13–18
22. Benster B, Carey A, Wadsworth F, Vashisht A, Domoney C, Studd J. A double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women. Menopause Int 2009; 15: 63–69
23. Rossouw JE, Anderson GL, Prentice R, LaCroix AZ, Kooperberg C, Stefanick ML. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized control trial. JAMA 2002; 288: 321–33
24. Warren R. Hormones and mammographic breast density. Maturitas 2004; 49: 67–78
25. Landgren MB, Coelingh Bennink HJT, Helmond FA, Engelen S. Dose-response analysis of effects of tibolone on climacteric symptoms. BJOG: Int J Obstet Gynaecol 2002; 109: 1109–14
26. Baracat EC, Barbosa IC, Giordano MG,, et al. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability. Climacteric 2002; 5: 60–69
27. Hammar M, Christau S, Nathorst-Böös J, Rud T, Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. BJOG: Int J Obstet Gynaecol 1998; 105: 904–11
28. Kenemans P, Bundred NJ, Foidart J-M,, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009; 10: 135–46
29. Brück K, Zeisberger E. Adaptive changes in thermoregulation and their neuropharmacological basis. Pharmacol Therap 1987; 35: 163–215
30. Freedman RR, Woodward S, Sabharwal SC. [alpha]2-Adrenergic mechanism in menopausal hot flushes. Obstet Gynecol 1990; 76: 573–578
31. Delaunay L, Bonnet F, Liu N, Beydon L, Catoire P, Sessler D. Clonidine comparably decreases the thermoregulatory thresholds for vasoconstriction and shivering in humans. Anesthesiology 1993; 79: 470–474
32. Delaunay L, Herail T, Sessler DI, Lienhart A, Bonnet F. Clonidine increases the sweating threshold, but does not reduce the gain of sweating. Anesth Analg 1996, 1996; 83: 844–848
33. Schmitt H, Schmitt MH. Localization of the hypotensive effect of 2-(2-6-dichlorophenylamino)-2-imidazoline hydrochloride (St 155, catapresan). Eur J Pharmacol 1969; 6: 8–12
34. Schindler AE, Muller D, Keller E, Goser R, Runkel F. Studies with clonidine (Dixarit) in menopausal women. Arch Gynecol 1979; 227: 341–347
35. Tulandi T, Lal S, Kinch RA. Effect of intravenous clonifdine on menopausal flushing and luteinising hormone secretion. Br J Obstet Gynaecol 1983; 90: 854–857
36. Claydon JR, Bell JW, Pollard P. Menopausal flushing: double-blind trial of a non-hormonal medication. Br Med J 1974; 1: 409–12
37. Ginsburg J, O’Reilly B, Swinhoe J. Effect of oral clonidine on human cardiovascular responsiveness: a possible explanation of the therapeutic action of the drug in menopausal flushing and migraine. Br J Obstet Gynaecol 1985; 92: 1169–75
38. Nelson HD, Vesco KK, Haney E,, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006; 295: 2057–71
39. Fink G, Sumner BEH. Estrogen and mental state. Nature 1996; 383: 306
40. Kugaya A, Epperson CN, Zoghbi S,, et al. Increase in prefrontal cortex Serotonin2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry 2003; 160: 1522–4
41. Moses EL, Drevets WC, Smith G,, et al. Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biol Psychiatry 2000; 48: 854–60
42. Compton J, Travis MJ, Norbury R,, et al. Long-term estrogen therapy and 5-HT2A receptor binding in postmenopausal women; a single photon emission tomography (SPET) study. Hormones Behav 2008; 53: 61–68
43. Stearns V, Slack R, Greep N,, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005; 23: 6919–30
44. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes a randomized controlled trial. JAMA 2003; 289: 2827–34
45. Loprinzi CL, Kugler JW, Sloan JA,, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000; 356: 2059–63
46. Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005; 105: 161–166
47. Loibl S, Schwedler K, von Minckwitz G, Strohmeier R, Mehta KM, Kaufmann M. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients – a double-blind, randomised study. Ann Oncol 2007; 18: 689–93
48. Loprinzi CL, Sloan JA, Perez EA,, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002; 20: 1578–83
49. Suvanto-Luukkonen E, Koivunen R, Sundstrom H,, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005; 12: 18–26
50. Deecher DC, Alfinito PD, Leventhal L. Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhbitor desvenlafaxine succinate in ovariectomised rodent models. Endocrinology 2007; 148: 1376–83
51. Speroff L, Gass M, Constantine GD, Olivier S, Investigators S. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008; 111: 77–87
52. Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009; 200: 172e1–17e10
53. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, OBach RS, Greenblatt DG. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Distr 2003; 31: 289–93
54. Kelly CM, Juurlink DN, Gomes T,, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010; 340: c693
55. Authors not listed. In brief: tamoxifen and SSRI interaction. Med Lett Drugs Ther 2009; 51: 45
56. Lash TL, Cronin-Fenton D, Ahern TP,, et al. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol 2010; 49: 305–12
57. Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 2009; 70: 1688–97
58. Guttuso JT. Gabapentin's effects on hot flashes and hypothermia. Neurology 2000; 54: 2161–3
59. Pandya KJ, Morrow GR, Roscoe JA,, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005; 366: 818–24
60. Guttuso JT, Kurlan R, McDermott P, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomised controlled trial. Obstet Gynecol 2003; 101: 337–45
61. Reddy SY, Warner H, Guttuso JT,, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006; 108: 41–48
62. Barton DL, Loprinzi CL, Quella SK,, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998; 16: 495–500
63. McBane S. Easing vasomotor symptoms: besides HRT, what works? JAAPA 2008; 21: 26–32
64. Wong VCK, Lim CED, Luo X, Wong WSF. Current alternative and complementary therapies used in menopause. Gynecol Endocrinol 2009; 25: 166–74
65. Osmers R, Friede M, Liske E, Schnitker J, Freudenstein J, Henneicke-von Zepelin H. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol 2005; 105: 1074–83
66. Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2005; 145: 869–79
67. Davis VL, Jayo MJ, Ho A,, et al. Black cohosh increases metastatic mammary cancer in transgenic mice expressing c-erbB2. Cancer Res 2008; 68: 8377–83
68. Teschke R, Schwarzenboeck A. Suspected hepatotoxicity by Cimicifugae racemosae rhizoma (black cohosh, root): critical analysis and structured causality assessment. Phytomedicine 2009; 16: 72–84
69. Lee MS, Shin B-C, Ernst E. Acupuncture for treating menopausal hot flushes: a systematic review. Climacteric 2009; 12: 16–25
70. Daley A, Stokes-Lampard H, Mutrie N, MacArthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2007; (4): CD006108
71. Miller PD, Chines AA, Christiansen C,, et al. Effects of Bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Mineral Res 2008; 23: 525–35
72. Komm BS, Kharode YP, Bodine PVN, Harris HA, Miller CP, Lyttle CR. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005; 146: 3999–4008
73. Ronkin S, Northington R, Baracat E,, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005; 105: 1397–404
74. Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009; 16: 1083–1124
75. Pickar JH, Yeh IT, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009; 93: 1018–24
76. Lobo RA, Pinkerton JV, Gass MLS,, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009; 92: 1025–38
77. Hendy MS, Cockrill B, Sherwood Burge P. The effects of naloxone infusion and stellate ganglion blockade on hot flushes in the human male. Maturitas 1985; 7: 169–74
78. Lipov EG, Joshi JR, Sanders S,, et al. Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study. Lancet Oncol 2008; 9: 523–32
79. Lipov EG, Joshi JR, Xie H, Slavin KV. Updated findings on the effects of stellate-ganglion block on hot flushes and night awakenings. Lancet Oncol 2008; 9: 819–20
80. Liu ZYZ, Zhu M, Huo J. Estrogenicity of black cohosh (Cimicifuga racemosa) and its effect on estrogen receptor level in human breast cancer MCF-7 cells. Wei Sheng Yan Jiu 2001; 30: 77–80
81. Rees M. Alternative treatments for the menopause. Best Prac Res Clin Obstet Gynaecol 2009; 23: 151–61